Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press2610.17650/1726-9776-2010-6-1-59-64REVIEWОБЗОРРОЛЬ ВЫПОЛНЕНИЯ ПОВТОРНОЙ ТРАНСУРЕТРАЛЬНОЙ РЕЗЕКЦИИ В ЛЕЧЕНИИ БОЛЬНЫХ РАКОМ МОЧЕВОГО ПУЗЫРЯ БЕЗ МЫШЕЧНОЙ ИНВАЗИИРОЛЬ ВЫПОЛНЕНИЯ ПОВТОРНОЙ ТРАНСУРЕТРАЛЬНОЙ РЕЗЕКЦИИ В ЛЕЧЕНИИ БОЛЬНЫХ РАКОМ МОЧЕВОГО ПУЗЫРЯ БЕЗ МЫШЕЧНОЙ ИНВАЗИИRolevichA. I.РолевичА. И.
Russian Federation
SukonkoO. G.СуконкоО. Г.
Russian Federation
KrasnyS. A.КрасныйС. А.
Russian Federation
StrotskyA. V.СтроцкийА. В.
Russian Federation
N.N. Alexandrov Belarussian Research and Practice Center of Oncology and Medical Radiology, Minsk, Republic of BelarusРНПЦ ОиМР им. Н.Н. Александрова, Минск, Республика Беларусь300320106159642407201424072014https://oncourology.abvpress.ru/oncur/article/view/26

To evaluate the role of the repeat transurethral resection (TUR) of the bladder in the management of non-muscle invasive bladder cancer (NMIBC), the medical literature was sought for, by using the PubMed database. The selected full text sources were analyzed. Repeat TUR carried out 1-6 weeks after primary surgery permits detection of residual tumor in 33-76% of cases, identification of muscle invasive bladder cancer in 4-28% of the patients with the primary diagnosis of NMIBC, more precise estimation of tumor extent, and modification of treatment policy in 4-33% of cases. Furthermore, repeat TUR allows estimation of the risk of further cancer progression and selection of patients for immediate radical cystectomy. Overall, this approach can improve the results of treatment of patients with NMIBC.

To evaluate the role of the repeat transurethral resection (TUR) of the bladder in the management of non-muscle invasive bladder cancer (NMIBC), the medical literature was sought for, by using the PubMed database. The selected full text sources were analyzed. Repeat TUR carried out 1-6 weeks after primary surgery permits detection of residual tumor in 33-76% of cases, identification of muscle invasive bladder cancer in 4-28% of the patients with the primary diagnosis of NMIBC, more precise estimation of tumor extent, and modification of treatment policy in 4-33% of cases. Furthermore, repeat TUR allows estimation of the risk of further cancer progression and selection of patients for immediate radical cystectomy. Overall, this approach can improve the results of treatment of patients with NMIBC.

repeat transurethral resection of the bladderinvasiverecurrencetreatment policy correction1. Поляков С.М., Левин Л.Ф., Шебеко Н.Г. Злокачественные новообразования в Беларуси, 1997-2006. Под ред. А.А. Граковича., И.В. Залуцкого. Минск: БЕЛЦМТ, 2007.Поляков С.М., Левин Л.Ф., Шебеко Н.Г. Злокачественные новообразования в Беларуси, 1997-2006. Под ред. А.А. Граковича., И.В. Залуцкого. Минск: БЕЛЦМТ, 2007.2. Brausi M., Collette L., Kurth K. et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 2002;41:523-31.Brausi M., Collette L., Kurth K. et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 2002;41:523-31.3. Kriegmair M., Baumgartner R., Knuchel R. et al. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol 1996;155:105-9.Kriegmair M., Baumgartner R., Knuchel R. et al. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol 1996;155:105-9.4. Zaak D., Kriegmair M., Stepp H. et al. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: Results of 1012 fluorescence endoscopies. Urology 2001;57:690-4.Zaak D., Kriegmair M., Stepp H. et al. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: Results of 1012 fluorescence endoscopies. Urology 2001;57:690-4.5. Schmidbauer J., Witjes F., Schmeller N. et al. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004;171:135-8.Schmidbauer J., Witjes F., Schmeller N. et al. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004;171:135-8.6. KlКn R., Loy V., Huland H. Residual tumour discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J Urol 1991;146:316-8.KlКn R., Loy V., Huland H. Residual tumour discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J Urol 1991;146:316-8.7. Herr H.W. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999;162:74-6.Herr H.W. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999;162:74-6.8. Brauers A., Buttner R., Jakse G. Second resection and prognosis in primary high risk superficial bladder cancer. J Urol 2001;165:808-10.Brauers A., Buttner R., Jakse G. Second resection and prognosis in primary high risk superficial bladder cancer. J Urol 2001;165:808-10.9. Rigaud J., Karam G., Braud G. et al. Tumeurs de vessie T1: intОrРt d'une deuxiПme rОsection endoscopique. Prog Urol 2002;12:27-30.Rigaud J., Karam G., Braud G. et al. Tumeurs de vessie T1: intОrРt d'une deuxiПme rОsection endoscopique. Prog Urol 2002;12:27-30.10. Schips L., Augustin H., Zigeuner R. et al. Is repeat transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology 2002;59:220-3.Schips L., Augustin H., Zigeuner R. et al. Is repeat transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology 2002;59:220-3.11. Grimm M.-O., Steinhoff C., Simon X. et al. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 2003;170:433-7.Grimm M.-O., Steinhoff C., Simon X. et al. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 2003;170:433-7.12. Divrik T., Yildirim U., Eroglu A. et al. Is a Second transurethral resection necessary for newly diagnosed pT1 bladder cancer? J Urol 2006;175:1258-61.Divrik T., Yildirim U., Eroglu A. et al. Is a Second transurethral resection necessary for newly diagnosed pT1 bladder cancer? J Urol 2006;175:1258-61.13. Schwaibold H., Sivalingam S., May F. et al. The value of a second transurethral resection for T1 bladder cancer. BJU Int 2006;97:1199-201.Schwaibold H., Sivalingam S., May F. et al. The value of a second transurethral resection for T1 bladder cancer. BJU Int 2006;97:1199-201.14. Dutta S., Smith Jr. J., Shappell S. et al. Clinical under staging of high risk nonmuscle-invasive urothelial carcinoma treated with radical cystectomy. J Urol 2001;166:490-3.Dutta S., Smith Jr. J., Shappell S. et al. Clinical under staging of high risk nonmuscle-invasive urothelial carcinoma treated with radical cystectomy. J Urol 2001;166:490-3.15. Bianco Jr. F., Justa D., Grignon D. Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. Urol Oncol 2004;22:290-4.Bianco Jr. F., Justa D., Grignon D. Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. Urol Oncol 2004;22:290-4.16. Huguet J., Crego M., Sabate S. et al. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: Pre-cystectomy prostate involvement as a prognostic factor. Eur Urol 2005;48:53-9.Huguet J., Crego M., Sabate S. et al. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: Pre-cystectomy prostate involvement as a prognostic factor. Eur Urol 2005;48:53-9.17. Ficarra V., Dalpiaz O., Alrabi N. et al. Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma. BJU Int 2005;95:786-90.Ficarra V., Dalpiaz O., Alrabi N. et al. Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma. BJU Int 2005;95:786-90.18. Chang S., Cookson M. Non-muscleinvasive bladder cancer: the role of radical cystectomy. Urology 2005;66:917-22.Chang S., Cookson M. Non-muscleinvasive bladder cancer: the role of radical cystectomy. Urology 2005;66:917-22.19. Kamat A., Gee J., Dinney C. et al. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol 2006;175:881-5.Kamat A., Gee J., Dinney C. et al. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol 2006;175:881-5.20. Herr H.W., Donat M. A re-staging transurethral resection predicts early progression of superficial bladder cancer. BJU Int 2006;97:1194-8.Herr H.W., Donat M. A re-staging transurethral resection predicts early progression of superficial bladder cancer. BJU Int 2006;97:1194-8.21. Herr H.W. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. J Urol 2005;174:2134-7.Herr H.W. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. J Urol 2005;174:2134-7.22. Divrik T., Yildirim Ж., Zorlu F. et al. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol 2006;175:1641-4.Divrik T., Yildirim Ж., Zorlu F. et al. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol 2006;175:1641-4.23. El-Abbady A., Shoukry M., Hanno A. et al. Repeated transurethral resection of recurrent superficial bladder tumors. Does it affect spread and stage of the tumour? Scan J Urol Nephrol 2002;36:60-2.El-Abbady A., Shoukry M., Hanno A. et al. Repeated transurethral resection of recurrent superficial bladder tumors. Does it affect spread and stage of the tumour? Scan J Urol Nephrol 2002;36:60-2.24. Hall C., Chang S., Dalbagni G. et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007;178:2314-30.Hall C., Chang S., Dalbagni G. et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007;178:2314-30.25. Oosterlinck W., van der Meijden A., Sylvester R. et al. Guidelines on Ta/T1 (non-muscle invasive) bladder cancer. Mode of access: http://www.uroweb.org/fileadmin/user_upl oad/Guidelines/05%20TaT1%20Bladder% 20Cancer.pdf. Date of access: 17.02.2008Oosterlinck W., van der Meijden A., Sylvester R. et al. Guidelines on Ta/T1 (non-muscle invasive) bladder cancer. Mode of access: http://www.uroweb.org/fileadmin/user_upl oad/Guidelines/05%20TaT1%20Bladder% 20Cancer.pdf. Date of access: 17.02.200826. Nieder A., Brausi M., Lamm D. et al. Management of stage T1 tumors of the bladder: international consensus panel. Urology 2005;66(Suppl 6A):108-25.Nieder A., Brausi M., Lamm D. et al. Management of stage T1 tumors of the bladder: international consensus panel. Urology 2005;66(Suppl 6A):108-25.27. Sylvester R., Van Der Meijden A., Witjes J. et al. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 2005;66(Suppl 6A):90-107.Sylvester R., Van Der Meijden A., Witjes J. et al. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 2005;66(Suppl 6A):90-107.